A phase I/II trial of ABTL0812 in children with relapsed/refractory neuroblastoma and other solid tumours

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504246-64-02

Acronym

ETNA

Enrollment

Registered

2024-11-12

Start date

2025-06-04

Completion date

Unknown

Last updated

2025-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/refractory neuroblastoma and other solid tumours

Brief summary

Incidence of dose limiting toxicities assessed during the first cycle of study treatment of ABTL0182 (cohorts A and B).

Interventions

DRUGTEMOZOLOMIDE

DRUGABTL0812

DRUGIRINOTECAN

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Incidence of dose limiting toxicities assessed during the first cycle of study treatment of ABTL0182 (cohorts A and B).	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026